Efficient vs. structured biodiversity inventories: reptiles in a Mexican dry scrubland as a case study

Many sampling methods allow the study of species richness and diversity in biological communities, but it is not known whether a single method can determine both the number and diversity of species in an unbiased and efficient way. Here we assess whether the least biased and most efficient method to determine reptile species richness in a Mexican dry scrubland is also the best method to estimate species diversity. The local assemblage was composed of 10 species, with the Mexican mud turtle (Kinosterton integrum) and the Jalapa spiny lizard (Sceloropus jalapae) being the dominant ones. Microhabitat surveys (MHS) were the most accurate and the most efficient method to estimate species richness, but they over–estimated species diversity (+67.1 %) as much as the other sampling methods, i.e., transect surveys and pitfall–trap stations, under–estimated it (–59 %). Our study shows that the best sampling method to determine the number of species in local assemblages may not be the best method to study species diversity. Although combining different sampling methods can increase the project costs in terms of time, effort and money, the use of structured inventories is recommended for the analysis of species diversity

Assessing non–parametric estimators of species richness. A case study with birds in green areas of the city of Puebla, Mexico

Nuestro objetivo fue evaluar el desempeño de estimadores no paramétricos de la riqueza de especies con datos reales. Durante la temporada de cría de 2003 censamos las comunidades de aves en dos áreas verdes de la ciudad de Puebla (México), y obtuvimos las corres¬pondientes curvas de rarefacción, que fueron ajustadas a dos funciones de acumulación de especies no asintóticas y siete asintóticas. Según criterios de la teoría de la información, la función de acumulación de Weibull o la Beta–P fueron las que mejor describieron estas curvas de acumulación, y asumimos que sus asíntotas estimaron la riqueza real en los dos sitios. Después evaluamos el sesgo, la precisión y la exactitud de cinco estimadores no paramétricos de la riqueza de especies (ICE, Chao 2, Jackknife 1, Jackknife 2 y Bootstrap) para esfuerzos de muestreo crecientes (1–53 unidades de censo). Todos los estimadores no paramétricos aquí evaluados subestimaron la riqueza asintótica la mayor parte del tiempo, en especial en una de las comunidades. Sin embargo, tras combinar los datos de los dos sitios, sólo ICE, Jackknife 1 y Jackknife 2 mostraron sesgos menores al 10% con algún esfuerzo de muestreo, aunque únicamente Jackknife 1 tuvo una exactitud global alta (error medio relativo al cuadradox100 &lt; 5%), incluso con esfuerzos de muestreo bajos (cerca del 20% del total de las unidades de censo). En conclusión, proponemos que el estimador no paramétrico Jackknife 1 puede usarse como un límite inferior de la riqueza de especies de aves en áreas urbanas similares a las de nuestro estudio. Palabras clave: Exactitud, Sesgo, Biodiversidad, Aves, Inventarios, Jackknife, Precisión, Urbanización.Nuestro objetivo fue evaluar el desempeño de estimadores no paramétricos de la riqueza de especies con datos reales. Durante la temporada de cría de 2003 censamos las comunidades de aves en dos áreas verdes de la ciudad de Puebla (México), y obtuvimos las corres¬pondientes curvas de rarefacción, que fueron ajustadas a dos funciones de acumulación de especies no asintóticas y siete asintóticas. Según criterios de la teoría de la información, la función de acumulación de Weibull o la Beta–P fueron las que mejor describieron estas curvas de acumulación, y asumimos que sus asíntotas estimaron la riqueza real en los dos sitios. Después evaluamos el sesgo, la precisión y la exactitud de cinco estimadores no paramétricos de la riqueza de especies (ICE, Chao 2, Jackknife 1, Jackknife 2 y Bootstrap) para esfuerzos de muestreo crecientes (1–53 unidades de censo). Todos los estimadores no paramétricos aquí evaluados subestimaron la riqueza asintótica la mayor parte del tiempo, en especial en una de las comunidades. Sin embargo, tras combinar los datos de los dos sitios, sólo ICE, Jackknife 1 y Jackknife 2 mostraron sesgos menores al 10% con algún esfuerzo de muestreo, aunque únicamente Jackknife 1 tuvo una exactitud global alta (error medio relativo al cuadradox100 &lt; 5%), incluso con esfuerzos de muestreo bajos (cerca del 20% del total de las unidades de censo). En conclusión, proponemos que el estimador no paramétrico Jackknife 1 puede usarse como un límite inferior de la riqueza de especies de aves en áreas urbanas similares a las de nuestro estudio. Palabras clave: Exactitud, Sesgo, Biodiversidad, Aves, Inventarios, Jackknife, Precisión, Urbanización.Our objective was to evaluate the performance of non–parametric estimators of spe¬cies richness with real data. During the 2003 breeding season, bird communities were sampled in two green areas in the city of Puebla (Mexico), and the corresponding sample–based rarefaction curves were obtained. Mean data were adjusted to two non–asymptotic and seven asymptotic accumulation functions, and the best model was selected by means of reliability criteria in information theory. The cumulative Weibull and the Beta–P functions were the best–fit models. Bias, precision and accuracy of five non–parametric estimators of species richness (ICE, Chao2, Jackknife 1, Jackknife 2, and Bootstrap) were then assessed for increasing sampling efforts (1–53 sampling units) against the asymptote of the selected accumulation functions. All the non–parametric estimators here evaluated underestimated true richness most of the time, specially in one of the sites. However, after combining data from the two assemblages, only ICE, and Jackknife 1 and 2 exhibited bias below 10% with different sampling efforts, and only Jackknife 1 was globally accurate (scaled mean squared errorx100< 5%, even with low sampling efforts, ca. 20% of the total). Therefore, we propose using the Jackknife 1 non–parametric estimator as a lower limit to measure bird species richness in urban sites similar to those in the present study. Key words: Accuracy, Bias, Biodiversity, Birds, Inventories, Jackknife, Precision, Urbanization

Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology

To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS).Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, classified according to baseline presence [Gd+, n=16] or absence [Gd-, n=53] of gadolinium-enhancing lesions in brain MRI. Ten Gd+ (62.5%) and 41 Gd- patients (77.4%) showed non-evidence of disease activity (NEDA) defined as no disability progression or new MRI lesions after 1 year of treatment. Blood immune cell subsets were characterized by flow cytometry, serum immunoglobulins by nephelometry, and serum neurofilament light-chains (sNfL) by SIMOA. Statistical analyses were corrected with the Bonferroni formula.More than 60% of patients reached NEDA after a year of treatment, regardless of their baseline characteristics. In Gd+ patients, it associated with a low repopulation rate of inflammatory B cells accompanied by a reduction of sNfL values 6 months after their first ocrelizumab dose. Patients in Gd- group also had low B cell numbers and sNfL values 6 months after initiating treatment, independent of their treatment response. In these patients, NEDA status was associated with a tolerogenic remodeling of the T and innate immune cell compartments, and with a clear increase of serum IgA levels.Baseline inflammation influences which immunological pathways predominate in patients with PPMS. Inflammatory B cells played a pivotal role in the Gd+ group and inflammatory T and innate immune cells in Gd- patients. B cell depletion can modulate both mechanisms.Copyright © 2022 Fernández-Velasco, Monreal, Kuhle, Meca-Lallana, Meca-Lallana, Izquierdo, Oreja-Guevara, Gascón-Giménez, Sainz de la Maza, Walo-Delgado, Lapuente-Suanzes, Maceski, Rodríguez-Martín, Roldán, Villarrubia, Saiz, Blanco, Diaz-Pérez, Valero-López, Diaz-Diaz, Aladro, Brieva, Íñiguez, González-Suárez, Rodríguez de Antonio, García-Domínguez, Sabin, Llufriu, Masjuan, Costa-Frossard and Villar

Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

Introducción: Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europeade Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosismúltiple remitente recurrente.Objetivo: Elaborar un documento de consenso sobre el manejo de alemtuzumab en la práctica clínica habitual, que sea de aplicación en el ámbito español.Desarrollo: Un grupo de expertos en esclerosis múltiple revisó las publicaciones disponibles hasta diciembre de 2017, de tratamiento con alemtuzumab y esclerosis múltiple. Se incluyeron trabajos sobre eficacia, efectividad y seguridad, despistaje de infecciones y vacunación, admi-nistración y monitorización. La propuesta inicial de recomendaciones fue desarrollada por un grupo coordinador con base en la evidencia disponible y en su experiencia clínica. El proceso de consenso se llevó a cabo en 2 etapas; se estableció como porcentaje inicial de acuerdo grupal el 80%. El documento final con todas las recomendaciones acordadas por el grupo de trabajo se sometió a revisión externa y los comentarios recibidos fueron considerados por el grupo coordinador. Conclusiones: El documento aportado pretende ser una herramienta útil para facilitar el manejo del fármaco en condiciones de práctica clínica habitualtIntroduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. Objective: A consensus document was drafted on the management of alemtuzumab in routineclinical practice in Spain. Development: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017. The included studies assessed the drug’s efficacy, effectiveness, and safety; screening for infections and vaccination; and administration and monitoring aspects. The initial proposed recommendations were developed by a coordinating group and based on the available evidence and their clinical experience. The consensus process was carried out in 2 stages, with the initial threshold percentage for group agreement established at 80%. The final document with all the recom-mendations agreed by the working group was submitted for external review and the comments received were considered by the coordinating group. Conclusion: The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practiceLa elaboración de este manuscrito ha sido financiada por Sanofi-Genzym

Resilience Management for Healthy Cities in a Changing Climate

Cities are experiencing multiple impacts from global environmental change, and the degree to which they will need to cope with and adapt to these challenges will continue to increase. We argue that a ‘complex systems and resilience management’ view may significantly help guide future urban development through innovative integration of, for example, grey, blue and green infrastructure embedded in flexible institutions (both formal and informal) for multi-functionality and improved health. For instance, the urban heat island effect will further increase city-centre temperatures during projected more frequent and intense heat waves. The elderly and people with chronic cardiovascular and respiratory diseases are particularly vulnerable to heat. Integrating vegetation and especially trees in the urban infrastructure helps reduce temperatures by shading and evapotranspiration. Great complexity and uncertainty of urban social-ecological systems are behind this heatwave-health nexus, and they need to be addressed in a more comprehensive manner. We argue that a systems perspective can lead to innovative designs of new urban infrastructure and the redesign of existing structures. Particularly to promoting the integration of grey, green and blue infrastructure in urban planning through institutional innovation and structural reorganization of knowledge-action systems may significantly enhance prospects for improved urban health and greater resilience under various scenarios of climate change.info:eu-repo/semantics/publishedVersio

SARS-CoV-2 Infection in Multiple Sclerosis

To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04-1.17) as the only independent risk factor for a fatal outcome. This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal diseas

Consenso de expertos sobre el uso de alemtuzumab en la práctica clínica diaria en España

Introducción: Alemtuzumab es un fármaco de alta eficacia aprobado por la Agencia Europea de Medicamentos como tratamiento modificador de la enfermedad en pacientes con esclerosis múltiple remitente recurrente. Objetivo: Elaborar un documento de consenso sobre el manejo de alemtuzumab en la práctica clínica habitual, que sea de aplicación en el ámbito español. Desarrollo: Un grupo de expertos en esclerosis múltiple revisó las publicaciones disponibles hasta diciembre de 2017, de tratamiento con alemtuzumab y esclerosis múltiple. Se incluyeron trabajos sobre eficacia, efectividad y seguridad, despistaje de infecciones y vacunación, administración y monitorización. La propuesta inicial de recomendaciones fue desarrollada por un grupo coordinador con base en la evidencia disponible y en su experiencia clínica. El proceso de consenso se llevó a cabo en 2 etapas; se estableció como porcentaje inicial de acuerdo grupal el 80%. El documento final con todas las recomendaciones acordadas por el grupo de trabajo se sometió a revisión externa y los comentarios recibidos fueron considerados por el grupo coordinador. Conclusiones: El documento aportado pretende ser una herramienta útil para facilitar el manejo del fármaco en condiciones de práctica clínica habitual.Introduction: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. Objective: A consensus document was drafted on the management of alemtuzumab in routine clinical practice in Spain. Development: A group of multiple sclerosis specialists reviewed articles addressing treatment with alemtuzumab in patients with multiple sclerosis and published before December 2017. The included studies assessed the drug's efficacy, effectiveness, and safety; screening for infections and vaccination; and administration and monitoring aspects. The initial proposed recommendations were developed by a coordinating group and based on the available evidence and their clinical experience. The consensus process was carried out in 2 stages, with the initial threshold percentage for group agreement established at 80%. The final document with all the recommendations agreed by the working group was submitted for external review and the comments received were considered by the coordinating group. Conclusion: The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice